July 12, 2018
GCA Advises Cheplapharm on Its Term Loan B Refinancing
GCA acted as exclusive debt advisor to Cheplapharm Arzneimittel GmbH on its successful debut on the syndicated and rated Term Loan B market.
Cheplapharm is a pharmaceutical company that offers branded off-patent specialty products. The Group has a unique international footprint and a broad portfolio of over 70 products across more than 10 therapeutic areas. Cheplapharm focuses on acquiring original well-established off-patent niche and legacy branded pharmaceuticals from large pharmaceutical companies and creating value through its global footprint.
The new credit facilities ensure that the Group's long-term financing is flexible and sustainably secured, with a significant amount of additional liquidity available to finance future M&A projects.
Sebastian F. Braun, CEO of Cheplapharm commented: "Following the successful establishment of a global partner network, Cheplapharm is now able to continue its long-standing success story due to the new financing structure by further scaling the business model."